Related Experiment Videos
Recombinant human erythropoietin dosage in children undergoing hemodialysis and continuous ambulatory peritoneal
M Sieniawska1, M Roszkowska-Blaim
1Department of Pediatrics and Nephrology, University Children's Hospital, Warsaw, Poland.
Insights
Erythropoietin (EPO) effectively treats anemia in children on continuous ambulatory peritoneal dialysis (CAPD) at a dose of 50 U/kg weekly. However, this dose is insufficient for children on hemodialysis (HD), who require higher EPO levels.
Area of Science:
- Pediatric Nephrology
- Hematology
- Renal Replacement Therapy
Background:
- Anemia is a common complication in children undergoing renal replacement therapy.
- Erythropoietin (EPO) is a key treatment for anemia in chronic kidney disease.
- Different dialysis modalities may impact EPO efficacy.
Purpose of the Study:
- To compare the efficacy of a standard subcutaneous erythropoietin (EPO) dose in pediatric patients on hemodialysis (HD) versus continuous ambulatory peritoneal dialysis (CAPD).
- To determine the optimal initial EPO dosage for pediatric anemia management in different dialysis settings.
Main Methods:
- A comparative study involving 11 children on HD and 8 children on CAPD.
- Initial treatment with subcutaneous EPO at 50 U/kg once weekly for 24 weeks.
- Monitoring of hemoglobin (Hb) and hematocrit (Hct) levels throughout the observation period.
Main Results:
- Children on CAPD showed significant increases in mean Hb (7.7 to 11.2 g/dl) and Hct (22.3 to 32.6%).
- Children on HD had smaller increases in mean Hb (7.7 to 9.3 g/dl) and Hct (22.7 to 27.6%).
- 87.5% of CAPD patients reached Hb >10 g/dl within 8 weeks, compared to only 10% of HD patients. All CAPD patients achieved target Hb by 12 weeks, while 7 HD patients required increased EPO doses (100 U/kg/week).
Conclusions:
- A subcutaneous EPO dose of 50 U/kg once weekly is effective for treating anemia in pediatric patients on CAPD.
- This standard EPO dose is insufficient for achieving target hemoglobin levels in pediatric patients on HD.
- Dosage adjustments are necessary for effective EPO therapy in pediatric hemodialysis patients.
Abstract:
The efficacy of erythropoietin (EPO) in 11 children on hemodialysis (HD) and 8 on continuous ambulatory peritoneal dialysis (CAPD) (mean age 11.8 years) was compared. The initial EPO dose was 50 U/kg s.c. once a week; the time of observation was 24 weeks. In the CAPD group, the mean hemoglobin (Hb) level increased from 7.7 +/- 0.2 to 11.2 +/- 0.6 g/dl (P < 0.001) and hematocrit (Hct) from 22.3 +/- 1.0 to 32.6 +/- 1.4% (P < 0.001), while in the HD group the mean Hb rose from 7.7 +/- 0.6 to 9.3 +/- 0.8 g/dl (P < 0.001) and mean Hct from 22.7 +/- 2.3 to 27.6 +/- 2.8% (P < 0.001) after 12 weeks of observation. An increase in Hb to over 10 g/dl was obtained in 87.5% of children on CAPD but in only 10% on HD after 8 weeks of EPO treatment. After 12 weeks of treatment, all children on CAPD had the target Hb level of more than 10 g/dl, while 7 children on HD required increased doses of EPO (100 U/kg per week). We conclude that the EPO dose of 50 u/kg given s.c. once a week is effective for children with anemia on CAPD but is insufficient for children on HD.